Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: AQST

Aquestive Therapeutics, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for AQST. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.65

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-20 11:28 UTC.

What Aquestive Therapeutics, Inc. does

Aquestive is a pharmaceutical company that develops and manufactures medicines using innovative drug delivery technologies, particularly its proprietary PharmFilm oral film platform. The company is advancing Anaphylm, a non-device epinephrine prodrug candidate for severe allergic reactions and anaphylaxis, along with other product candidates from its AdrenaVerse epinephrine prodrug platform. Aquestive manufactures four licensed commercialized products that are marketed by licensees globally, and operates manufacturing facilities in Indiana and research facilities in New Jersey.

Summarized from Aquestive Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.65

Revenue, margins & earnings

FY2021: net loss $71M on revenue $51M$51MFY2021FY2022: net loss $54M on revenue $48M$48MFY2022FY2023: net loss $8M on revenue $51M$51MFY2023FY2024: net loss $44M on revenue $58M$58MFY2024FY2025: net loss $84M on revenue $45M$45MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16President and CEOSale-25,000$105.6K
  • 2026-09-16President and CEOSale-25,000$120.5K
  • 2026-09-11Chief Commercial OfficerNon-Qualified Stock Option (right to buy)Option exercise-8,750—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Aquestive Therapeutics, Inc. do?

Aquestive is a pharmaceutical company that develops and manufactures medicines using innovative drug delivery technologies, particularly its proprietary PharmFilm oral film platform.

When did AQST last file with the SEC?

Aquestive Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 11:28 UTC. This page is also available as JSON at /api/data?ticker=AQST and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AQST and 5,000+ tickers.

Create a free account — keep AQST
For your agent
GET /api/data?ticker=AQST

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt